Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00187)
Name
Dexlansoprazole
Synonyms    Click to Show/Hide the Synonyms of This API
dexlansoprazole; (R)-Lansoprazole; 138530-94-6; dexilant; Kapidex; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; TAK-390; UNII-UYE4T5I70X; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; T-168390; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; TAK-390MR; C16H14F3N3O2S; 1H-Benzimidazole, 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; Dexlansoprazole (INN/USAN); Dexlansoprazole [USAN:INN]; (+)-lansoprazol; 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; Dexilant (TN); 1H-Benzimidazole, 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; Lansoprazole r-form; (+)-(R)-Lansoprazole; SCHEMBL44975; GTPL5487; CHEMBL1201863; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:135931; HMS3652C14; ZINC599734; BDBM50247930; HY-13662B; MFCD13196699; AKOS025290765; CCG-213301; DB05351; PB33188; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; NCGC00386267-03; AC-26449; AK170558; AS-18086; SW219466-1; D08903; Q-1374; AB01563023_01; AB01563023_02; Q5268339; UNII-0K5C5T2QPG component MJIHNNLFOKEZEW-RUZDIDTESA-N; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; (+)-2-((R)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1H-benzimidazole; (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzimidazole; 2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl]-1H-1,3-benzodiazole
Clinical Status
Approved
Disease Indication Gastro-oesophageal reflux disease ICD-11: DA22 [1]
PubChem CID
9578005
Formula
C16H14F3N3O2S
Canonical SMILES
CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
InChI
1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
InChIKey
MJIHNNLFOKEZEW-RUZDIDTESA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=9578005"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 369.4 Topological Polar Surface Area 87.1
XlogP 2.8 Complexity 480
Heavy Atom Count 25 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
Full List of Drug Formulations (DFMs) Containing This API
          Dexlansoprazole 30 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous citric acid; Lactose monohydrate; Sucralose; Glyceryl monostearate; Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Magnesium carbonate; Talc; Titanium dioxide; Triethyl citrate; Polysorbate 80; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (type h); Hydroxypropyl cellulose, low substituted; Hypromellose 2910 (6 mpa.s); Methacrylic acid - ethyl acrylate copolymer (1:1) type a; Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid 7:3:1 280000 mw); Polyethylene glycol 8000
                   Dosage Form Disintegrating Oral Tablet
                   Company Takeda Pharmaceuticals America
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sucralose DIG Info Carbonic anhydrase II (Ki = 300 nM) [2]
Kyselina citronova DIG Info Perilipin-1 (IC50 = 3708 nM) [3]
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [4]
Glyceryl monostearate DIG Info Prostate cancer LNCaP cells (IC50 > 100000 nM) [5]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [6]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [7]
          Dexlansoprazole 30 mg capsule Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Potassium chloride; Ferric oxide red; Magnesium carbonate; Sucrose; Talc; Titanium dioxide; Triethyl citrate; Hypromellose; Polysorbate 80; Silicon dioxide; Aluminum oxide; Carrageenan; Hydroxypropyl cellulose; Hydroxypropyl cellulose, low substituted; Hypromellose 2910 (15 cps); Polyethylene glycol 8000
                   Dosage Form Delayed Release Oral Capsule
                   Company Physicians Total Care
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [6]
Potassium chloride DIG Info Carbonic anhydrase IV (Ki = 90000 nM) [8]
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [9]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [6]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [7]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Potassium chloride; Ferric oxide red; Magnesium carbonate; Sucrose; Talc; Titanium dioxide; Triethyl citrate; Polysorbate 80; Silicon dioxide; Aluminum oxide; Carrageenan; Hydroxypropyl cellulose (1200000 mw); Hypromellose 2910 (6 mpa.s); Low-substituted hydroxypropyl cellulose, unspecified; Methacrylic acid - ethyl acrylate copolymer (1:1) type a; Methacrylic acid - methyl methacrylate copolymer (1:1); Methacrylic acid - methyl methacrylate copolymer (1:2); Polyethylene glycol 8000; Starch, corn
                   Dosage Form Delayed Release Oral Capsule
                   Company Takeda Pharmaceuticals America
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [6]
Potassium chloride DIG Info Carbonic anhydrase IV (Ki = 90000 nM) [8]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [6]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [7]
          Dexlansoprazole 60 mg capsule Click to Show/Hide the Full List of Formulation(s):          3 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Potassium chloride; Magnesium carbonate; Sucrose; Talc; Titanium dioxide; Triethyl citrate; Polysorbate 80; Silicon dioxide; Aluminum oxide; Carrageenan; Hydroxypropyl cellulose (1200000 mw); Hypromellose 2910 (6 mpa.s); Low-substituted hydroxypropyl cellulose, unspecified; Methacrylic acid - ethyl acrylate copolymer (1:1) type a; Methacrylic acid - methyl methacrylate copolymer (1:1); Methacrylic acid - methyl methacrylate copolymer (1:2); Polyethylene glycol 8000
                   Dosage Form Delayed Release Oral Capsule
                   Company Cardinal Health
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [6]
Potassium chloride DIG Info Carbonic anhydrase IV (Ki = 90000 nM) [8]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [6]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [7]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Potassium chloride; Magnesium carbonate; Sucrose; Talc; Titanium dioxide; Triethyl citrate; Polysorbate 80; Silicon dioxide; Aluminum oxide; Carrageenan; Hydroxypropyl cellulose; Hydroxypropyl cellulose, low substituted; Hypromelloses; Methacrylic acid - ethyl acrylate copolymer (1:1) type a; Methacrylic acid - methyl methacrylate copolymer (1:1); Methacrylic acid - methyl methacrylate copolymer (1:2); Polyethylene glycol 8000
                   Dosage Form Delayed Release Oral Capsule
                   Company Physicians Total Care
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [6]
Potassium chloride DIG Info Carbonic anhydrase IV (Ki = 90000 nM) [8]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [6]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [7]
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Potassium chloride; Magnesium carbonate; Sucrose; Talc; Titanium dioxide; Triethyl citrate; Polysorbate 80; Silicon dioxide; Aluminum oxide; Carrageenan; Hydroxypropyl cellulose (1200000 mw); Hypromellose 2910 (6 mpa.s); Low-substituted hydroxypropyl cellulose, unspecified; Methacrylic acid - ethyl acrylate copolymer (1:1) type a; Methacrylic acid - methyl methacrylate copolymer (1:1); Methacrylic acid - methyl methacrylate copolymer (1:2); Polyethylene glycol 8000; Starch, corn
                   Dosage Form Delayed Release Oral Capsule
                   Company Takeda Pharmaceuticals America
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [6]
Potassium chloride DIG Info Carbonic anhydrase IV (Ki = 90000 nM) [8]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [6]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [7]
References
1 FDA label for approved dexlansoprazole from the official website of the U.S. Food and Drug Administration.
2 Sweet Binders: Carbonic Anhydrase IX in Complex with Sucralose. ACS Med Chem Lett. 2018 May 10; 9(7):657-661.
3 PubChem BioAssay data set.
4 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
5 Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds. J Nat Prod. 2002 Feb; 65(2):206-9.
6 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
7 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.
8 Characterization and anions inhibition studies of an -carbonic anhydrase from the teleost fish Dicentrarchus labrax. Bioorg Med Chem. 2011 Jan 15; 19(2):744-8.
9 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.